Vycor’s Patented VBAS Minimally Invasive Neurosurgical Device Accepted by 12 New U.S. Hospitals This Year
BOCA RATON, FL — (Marketwired) — 04/29/14 — Vycor Medical, Inc. (“Vycor”) (OTCQB: VYCO), a
provider of innovative and superior neurosurgical and neurotherapeutic solutions, today announced
continued momentum and an increase in the number of hospitals that have approved use of Vycor’s
patented ViewSite? Brain Access System (“VBAS”) device. During this calendar year, VBAS has been
approved by 12 new U.S. hospitals and is now approved in more than 170 hospitals in the U.S. with
additional hospitals going through the approval process. To date, more than 5,000 surgeries have
been performed utilizing VBAS.
David Cantor, President of Vycor, commented, “Neurosurgeons continue to demand the VBAS system to
treat their patients, helping us to expand our global market presence. The patented, innovative
VBAS product continues to gain traction in both the U.S. and international markets and we remain
convinced that the VBAS device will become the ‘Standard of Care’ for brain retraction and access.”
VBAS is a suite of clear cylindrical disposable devices used to access target sites such as tumors
within the brain which provide a working channel during neurosurgery for their removal. The devices
are being used in brain surgeries in the
U.S. and internationally. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance
for brain and
spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU –
Class III), and Japan and is seeking or has partial regulatory approvals in India, Korea, Russia,
Taiwan and Vietnam. Vycor has 8 granted and 8 pending patents worldwide.
The VBAS system provides a minimally invasive approach into the brain, offering clinical advantages
that have been validated in various peer-reviewed articles and have enabled previously inoperable
procedures to take place, thereby saving and changing lives. The product’s minimally invasive
profile and clinical superiority has been documented in five studies including peer-reviewed
articles by leading institutions including John’s Hopkins University, University of Illinois at
Chicago, and the Cleveland Clinic (Pediatrics Department). Additional studies are anticipated in
the near future further supporting the products clinical benefits.
Traditional tools for brain retraction have not changed much in more than 50 years. Advantages of
the innovative Vycor VBAS over the long-established standard of care device, the “blade retractor”,
include:
- Provision of a minimally invasive approach into the brain which results in reduced “white
matter” damage to the surrounding tissue due to the products tubular shape. - VBAS applies rigid, constant and equally distributed pressure to the surrounding tissue.
- The tubular retractor provides enhanced visualization and more stable retraction of the
surrounding tissue. - Reported to result in reduced surgical time which results in lower costs of procedures and
improved surgical outcomes for patients.
A corporate video on the whole of the Vycor Group, which highlights VBAS and includes commentary
from several neurosurgeons, can be found at: http://player.vimeo.com/video/39903199
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded
company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior
surgical and therapeutic solutions and has a growing portfolio of FDA-cleared medical solutions
that are changing and improving lives every day. The Company operates two business units: Vycor
Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies
have exceptional sales growth potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
Vycor Medical’s ViewSite? Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally
invasive disposable devices that hold the potential for speedier, safer and more economical brain
surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access,
reduce patient risk, accelerate recovery and add tangible value to the professional medical
community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and
spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU –
Class III), and Japan and is seeking or has partial regulatory
approvals in India, Korea, Russia, Taiwan and Vietnam. For an overview of Vycor Medical’s VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation therapy and other medical
technologies that help improve and partially restore sight in patients with neurological vision
impairments. The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically
supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other
acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the
restoration of vision for neurologically induced vision loss and can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist. VRT also has CE Marking for the EU.
NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity
deep within the field defect.
In March 2014 the Company soft-launched NeuroEyeCoach? in the US, which is the first commercially
available saccadic therapy deliverable via the web to patients’ computers at their own homes. The
program is supported by more than four decades of scientific findings and was developed as
collaboration between the Company, and Josef Zihl, a NovaVision Scientific Advisor and world
thought leader in saccadic training and the pioneer of this computer based training technique. The
program is designed to result in a meaningful improvement in the patients visual search performance
resulting in improvements in their navigation and object finding skills. Given that NeuroEyeCoach?
addresses the patients difficulty with their eye movements
and their ability to integrate visual information while VRT focuses on the restoration of lost
vision the two therapies are highly complementary. For an overview of NovaVision see
http://player.vimeo.com/video/39765566
For the latest information on the company, including media and other coverage, and to learn more,
please go online at www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”,
“expect”, “should”, “believe”, and similar expressions are intended to identify forward- looking
statements. These forward-looking statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical’s actual results, performance
(financial or operating) or achievements to differ from the future results, performance (financial
or operating) or achievements expressed or implied by such forward- looking statements. The risks,
uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S.
Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical
herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor
Medical disclaims any obligation to update
forward-looking statements contained in this estimate, except as may be required by law.
Vycor Medical, Inc Investor Contacts:
Hayden IR
Brett Maas, Managing Partner (646) 536-7331
Email Contact
Or
Cameron Donahue, Partner (651) 653-1854
Email Contact
I would like to be contacted by your sales person
Reply →Please call Angela at 3056618288
I would like to be contacted by your sales person
Reply →Please call Angela at 3056618288